Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis

Aims/hypothesis Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) may reduce nephrolithiasis risk by increasing urine flow. We aimed to investigate whether initiation of SGLT2I was associated with reduced nephrolithiasis risk. Methods We conducted an active-comparator new-user cohort study using t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetologia 2021-07, Vol.64 (7), p.1563-1571
Hauptverfasser:	Kristensen, Kasper B., Henriksen, Daniel P., Hallas, Jesper, Pottegård, Anton, Lund, Lars C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Cohort analysis Cohort Studies Denmark - epidemiology Diabetes Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Diabetic Nephropathies - drug therapy Diabetic Nephropathies - epidemiology Diabetic Nephropathies - etiology Diabetic Nephropathies - prevention & control Emigration Female GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Health risks Human Physiology Humans Hypoglycemic Agents - therapeutic use Incidence Inhibitor drugs Internal Medicine Kidney stones Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Nephrolithiasis Nephrolithiasis - drug therapy Nephrolithiasis - epidemiology Nephrolithiasis - etiology Nephrolithiasis - prevention & control Observational studies Risk Factors Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Urination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!